TScan Therapeutics (TCRX) Debt Ratio (2022 - 2026)

TScan Therapeutics (TCRX) has 5 years of Debt Ratio data on file, last reported at 0.16 in Q1 2026.

• On a quarterly basis, Debt Ratio rose 67.13% year-over-year to 0.16 in Q1 2026; TTM through Mar 2026 was 0.16, a 67.13% increase from a year earlier, with the FY2025 full-year figure at 0.14, up 64.55% from the prior year.
• Debt Ratio for Q1 2026 stood at 0.16, up from 0.14 in the prior quarter.
• Over the last five years, Debt Ratio for TCRX reached as high as 0.18 in Q3 2022 and fell as low as 0.08 in Q2 2024.
• Historically, Debt Ratio has averaged 0.12 across 5 years, with a median of 0.11 in 2023.
• Across the five-year window, Debt Ratio tumbled 41.52% in 2023 and surged 67.13% in 2026, its largest moves.
• Year by year, Debt Ratio stood at 0.15 in 2022, then fell by 24.95% to 0.11 in 2023, then dropped by 21.73% to 0.09 in 2024, then soared by 64.55% to 0.14 in 2025, then increased by 13.68% to 0.16 in 2026.
• Per Business Quant data, the three most recent Debt Ratio figures were 0.16 in Q1 2026, 0.14 in Q4 2025, and 0.12 in Q3 2025.